Cumberland Pharmaceuticals has completed its shift from a company with a commercial drug business to one focused on developing medicines. After transferring its commercial brands and organization to Apotex Health, it is concentrating on its clinical pipeline and plans to seek U.S. approval for ifetroban to treat heart-muscle disease associated with Duchenne muscular dystrophy (DMD).
The company also highlighted results from a systemic-sclerosis trial and reported third-quarter and nine-month 2026 results. The available release text does not provide the trial findings or financial figures.
Key details
-
The Apotex transaction closed July 1. Cumberland received $100 million at closing, and its commercial brands and organization were integrated into Apotex’s U.S. branded business. Cumberland says the proceeds strengthened its balance sheet and allowed it to focus on drug development.
-
Cumberland plans to submit an application for ifetroban in DMD-related cardiomyopathy. The decision followed a pre-application meeting with the FDA. The agency granted the company’s request for a rolling review, allowing completed sections of the application to be submitted before the full package is ready. The company did not give a submission date.
-
The planned application will draw on clinical, safety and manufacturing information. Cumberland cited its Phase 2 FIGHT DMD trial, long-term data from an ongoing open-label extension, published preclinical research, manufacturing information and a safety database covering more than 1,400 people across about 30 clinical studies.
-
In the Phase 2 trial, the high-dose group showed a 5.4-percentage-point improvement in left ventricular ejection fraction, a measure of the heart’s pumping function, compared with a control group combining placebo-treated patients and propensity-score-matched natural-history patients. Cumberland reported a p-value of 0.002 and also said markers of cardiac damage declined.
-
The company reported no treatment-related serious adverse events or new safety concerns among DMD patients treated for up to 36 months across the trial and its extension. This describes the experience reported to date; it is not an FDA determination of safety or effectiveness.
-
Ifetroban has Orphan Drug, Rare Pediatric Disease and Fast Track designations. The FDA has conditionally accepted DYSCORBAN as the drug’s proposed proprietary name. These designations and the name acceptance do not amount to approval.
-
The release flagged top-line results from a systemic-sclerosis trial, but the available text does not include the results or describe the trial’s efficacy or safety findings.
What changes for investors
The transaction moves Cumberland’s commercial business into Apotex’s U.S. branded operation, while Cumberland retains a development-focused role backed by the $100 million in closing proceeds. Its near-term regulatory focus is now ifetroban for DMD-related cardiomyopathy. The company’s announcement is a plan to submit an application—not an approval—and the available update does not provide a filing timetable or the underlying systemic-sclerosis results.
